Creo Medical Group (LON:CREO) Stock Price Down 1.8% – Here’s What Happened

Creo Medical Group PLC (LON:CREO) shares traded down 1.8% on Thursday . The stock traded as low as GBX 13.50 and last traded at GBX 13.50. 2,707,456 shares were traded during trading, an increase of 209% from the average session volume of 875,276 shares. The stock had previously closed at GBX 13.75.

Analysts Set New Price Targets

Separately, Shore Capital Group reiterated a “house stock” rating and issued a GBX 40 price target on shares of Creo Medical Group in a research note on Tuesday, May 26th.

Creo Medical Group Stock Performance

The company has a market capitalization of £65.58 million, a P/E ratio of 13.50 and a beta of 1.62. The business has a 50 day moving average of GBX 12.76 and a 200 day moving average of GBX 12.61. The company has a quick ratio of 2.19, a current ratio of 3.22 and a debt-to-equity ratio of 8.20.

Creo Medical Group (LON:CREO) last released its quarterly earnings data on Friday, May 22nd. The company reported GBX (0.04) earnings per share (EPS) for the quarter. The firm had revenue of GBX 600 million during the quarter. Creo Medical Group had a return on equity of 9.56% and a net margin of 88.33%. On average, sell-side analysts predict that Creo Medical Group PLC will post -10.0800005 earnings per share for the current year.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.